FORMULATION AND IN-VITRO CHARACTERISATION OF SOLID – SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM (s-SNEDDS) OF RILPIVIRINE

Rilpivirine (RILP) is non-nucleoside reverse transcriptase inhibitor. It is indicated for the treatment of HIV-1 infection. The current investigation was aimed to formulation and evaluation of solid self nano emulsifying drug delivery system (S-SNEDDS) for Rilpivirine to enhance solubility and dissolution rate. Solubility of drug was determined in different vehicles. Pseudo ternary phase diagram generated using PEG 400, cremophore RH 40 and Transcutol 90. The S-SNEDDS was prepared by adsorbing the optimized liquid SNEDDS on to neusilin US2 as carrier. The S-SNEDDS characterized by micromeritic properties, differential scanning studies, percentage transmittance, emulsification time and zeta potential. The optimized formulation had shown globule size of 16.27 nm with PDI of 0.276, less emulsification time of 30.2sec, good % transmittance (97.152±0.414) and good in vitro release. The in vitro dissolution rate of the drug from the s-SNEDDS was three folds than that of the plain drug and its suspension respectively cumulative percentage of drug release was found to 96.9±2.66 in 90 minutes. Accelerated stability studies was performed at 40⁰C and 75%RH for s-SNEDDS of Rilpivirine found satisfactory for effect of dilution. Droplet size is 15.37 nm with PDI 0.252. Cumulative percentage drug release of Rilpivirine is 96.9±2.66 % at the end of 1month indicating no change in % drug release after stability study for 1month.